O'Harte
Finbarr Paul Mary O'Harte, Ballymoney GB
Patent application number | Description | Published |
---|---|---|
20100267628 | Analogs of Gastric Inhibitory Polypeptide and Their Use for Treatment of Diabetes - The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes. | 10-21-2010 |
Finbarr Paul Mary O'Harte, County Londonderry GB
Patent application number | Description | Published |
---|---|---|
20090286722 | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function - Peptide analogues and methods are provided for treating age-related symptoms of decreased pancreatic beta-cell function, including glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion. | 11-19-2009 |
Finbarr Paul Mary O'Harte, Portstewart GB
Patent application number | Description | Published |
---|---|---|
20090281032 | Modified CCK peptides - The invention concerns a peptide based on biologically active CCK-8. The peptide has improved characteristics for the treatment of at least one of obesity and type 2 diabetes and has the structure: | 11-12-2009 |
Finbarr Paul Mary O'Harte, Londonderry GB
Patent application number | Description | Published |
---|---|---|
20090170762 | Treatment of Diabetes Related Obesity - Peptide analogues and uses are provided for treating and preventing obesity and for treating, preventing and reversing weight gain and related metabolic disease, and promoting weight loss and weight maintenance, by administering a medicament comprising an antagonist of GIP receptor, which is a peptide analogue of GIP. | 07-02-2009 |
Finbarr P.m. O'Harte, Co. Londonderry GB
Patent application number | Description | Published |
---|---|---|
20100129934 | Glycated Insulin as a Biomarker for Diagnosis and Monitoring of Diabetes - One of the major pathophysiological consequences of long term elevation of plasma glucose in diabetes is an increase in the non-enzymatic glycation of proteins. Contrary to expectations the present inventors have determined that individuals with well controlled short duration diabetes have particularly high concentrations of glycated insulin which decrease with increased disease severity and duration of diabetes. Further, a small proportion of apparently normal healthy individuals exhibit high glycated insulin levels in line with expected incidence of diabetes in the population. Methods of predicting the onset of diabetes and for monitoring the progression of diabetes by measuring the concentration of Glycated Insulin and the progression of diabetes are disclosed. | 05-27-2010 |
Finbarr P.m. O'Harte, Portstewart GB
Patent application number | Description | Published |
---|---|---|
20150197550 | Therapeutic Uses of Dogfish Glucagon and Analogues Thereof - The present invention relates to peptides of 12 to 50 amino acids in length which incorporate the amino acid sequence MDNRRAK for use in the treatment of obesity, type-2 diabetes or metabolic syndrome. | 07-16-2015 |